June 4th, 2022, Dr. Matthew Galsky, a world-renowned urogenital oncologist, co-director of the Center of Excellence for Bladder Cancer at Tisch Cancer Institute and professor of Mount Sinai Hospital in New York , held a special discussion of three important studies of Disitamab Vedotin in Chicago, such special arrangements are rare in the history of ASCO meetings.


Since 2017, Disitamab Vedotin developed by RemeGen has been presented at the American Society of Clinical Oncology (ASCO) for many consecutive years, and continues to bring exciting clinical data to cancer patients around the world. At ASCO meeting this year, RemeGen announced the results of three clinical studies on Disitamab Vedotin in the form of  poster discussion, once again demonstrating its advantages in urothelial carcinoma.

In a word, Disitamab Vedotin showed excellent efficacy and controllable safety profile both in combination with PD-1 and in monotherapy. Firstly, the data of Disitamab Vedotin combined with PD-1 showed that patients with urothelial carcinoma could benefit regardless of the number of treatment lines and the expression status of HER2 and PD-L1. The results of this study also confirmed that Disitamab Vedotin combined with immunotherapy may become a leader in the field of combined therapy for urothelial carcinoma. Secondly, Disitamab Vedotin showed advantages in the treatment of urothelial carcinoma with high/low HER2 expression, and the data results exceeded the efficacy of existing drugs for advanced urothelial carcinoma, filling the treatment gap in the global landscape.

Meanwhile, the data also showed that Disitamab Vedotin has  good efficacy in patients with low HER2 expression, which demonstrates that Disitamab Vedotin has the characteristics of higher HER2 affinity and strong side-kill effect. Similar results were also obtained in gastric cancer, indicating that Disitamab Vedotin is expected to take the lead position in various solid tumors with low HER2 expression.